Navigation Links
InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
Date:9/4/2007

- Phase 1b trial expected to begin in September -

BRISBANE, Calif., Sept. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the amended Clinical Trial Authorization (CTA) related to the Phase 1b clinical trial of ITMN-191 (Roche-R7227) has been approved by the appropriate European regulatory authorities. InterMune also has received approval from the Ethics Committee of the institutions that will conduct the Phase 1b study. ITMN-191 is an orally available hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche.

InterMune expects that the Phase 1b multiple ascending dose (MAD) study will begin this month and expects to announce initial top-line viral kinetic and safety results from the first three dose cohorts of the MAD study in the first quarter of 2008.

Dan Welch, President and Chief Executive Officer of InterMune, said, "InterMune and Roche are pleased to announce that we have successfully secured the required regulatory approvals that enable us to initiate our very important Phase 1b multiple ascending dose study. By amending the Phase 1b protocol, we believe we have enhanced our ability to deliver the most robust Phase 1b results possible which we expect will place us in a stronger position to begin our Phase 2 trials."

In early May, InterMune announced that it would amend the CTA to take into consideration new information on competitive protease inhibitors, in-vitro and preclinical data on ITMN-191 and pharmacokinetic observations from a Phase 1a study that was completed in May of 2007. In that study, a higher than anticipated exposure of ITMN-191 in plasma was observed in subjects dosed with food, suggesting tha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- It is no secret ... third being overweight or obese gyms and supplement companies are ... the condition is primarily related to dietary issues and a ... the result of a glandular problem or even a vitamin ... common vitamin deficiency is a lack of vitamin b12 ...
(Date:5/20/2013)... May 20, 2013 /PRNewswire-iReach/ -- Today at American ... Christine Ginocchio discussed Specific Technologies ... rapid identification of microorganisms producing bloodstream infection. Dr. ... of the Division of Infectious Disease Diagnostics at ... not-for-profit, non-sectarian health system. (Photo: ...
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
Breaking Medicine Technology:USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:5/20/2013)... According to a May 6, 2013 CBS News article, ... tanning salons in the US may soon have to ... to see cancer warnings on indoor tanning beds ... for the use of indoor tanning and sun beds. The ... increasingly common over the last few decades (Go to goo.gl/TCT6m). ...
(Date:5/20/2013)... UT (PRWEB) May 20, 2013 Salt Lake ... of Select Health’s Select 25 winners for 2013. ... from Select Health. Know Greater Heroes is a leadership training ... schools to teach children how to eat right, be active, ... participate in the Know Greater Heroes program each year, and ...
(Date:5/20/2013)... May 20, 2013 The Muscular ... community leaders behind bars for good at an Executive ... beginning at 9 a.m. , More than 100 ... Lock-Up to benefit individuals and families affected by muscle ... city officials, local celebrities, realtors, doctors, attorneys, bankers, and ...
(Date:5/20/2013)... 2013 Dorland Health, a division ... fourth annual Case In Point Platinum Awards, recognizing ... ensuring the system is patient- and family-centric, safe ... and creative work across the healthcare system that ... transitions of care through effective care coordination across ...
(Date:5/20/2013)... Diego, CA (PRWEB) May 20, 2013 ... and around the world will make the pilgrimage to ... the 2nd annual Digital Health Summer Summit ... conference provides a unique forum to showcase the latest ... and best practices, and network with some of industry’s ...
Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4
... recommended by Bradley Kropp of Faculty of 1000 Medicine, ... the recovery of bowel function after gastrointestinal surgery ... decades. , Authors of the paper published in ... half of them 5 pieces of chewing gum per ...
... Conscious Americans Driving Dental Implant and Facial ... Millennium Research Group, WALTHAM, Mass., Feb. 27 ... Volumes 2008 report, dental implants,and facial aesthetic procedures ... rates (CAGR). This stands in stark contrast to ...
... Feb. 27 Avista Capital Partners, a leading,private ... Gerhard Kurz, a,40-year veteran of the offshore energy ... Mr. Kurz was most recently President and ... of marine support and,transportation services, in which the ...
... daily,Black History Month 2008 "Profile America" feature from the ... INSURANCE, Profile America for the 27th day of ... U.S. population can be measured in many ways. One ... annual median income,for African-American households is just under $32,000. ...
... The Walter and Eliza Hall,Institute of Medical Research ... company, Genentech, a leading biotechnology company,based in South ... tripartite research,collaboration to discover new anti-cancer drugs., ... leaders,in this field may increase the chance of ...
... ... Food, Feed, ... leadership changes to strengthen its leading biotechnology,position and better serve the ... feed and fuel markets., "Across its business segments, DuPont is ...
Cached Medicine News:Health News:Cosmetic Procedures Outpace All Other Surgical Procedures 2Health News:Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz 2Health News:Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz 3Health News:Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 3Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: